Matches in Nanopublications for { ?s ?p "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 14 of
14
with 100 items per page.
- NP515124.RAgVzAu2wJNTvPe_XnMg4EyRkkW1ZNynsr75bZWM8sANs130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP515124.RAgVzAu2wJNTvPe_XnMg4EyRkkW1ZNynsr75bZWM8sANs130_provenance.
- NP891781.RAe7PxCASyZJz1_m2doelvSbYP2Om8_mDKGgPeQDkGPw8130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP891781.RAe7PxCASyZJz1_m2doelvSbYP2Om8_mDKGgPeQDkGPw8130_provenance.
- assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP431302.RA1gdDrmwEtU3pUDnB4zji9g0SoetIdygFDFeiqwhMfnk130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP431302.RA1gdDrmwEtU3pUDnB4zji9g0SoetIdygFDFeiqwhMfnk130_provenance.
- NP801216.RA-W7IZBWU67MO887Rhfh2V75kCB_xyyrgKPfUmbLmvFo130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP801216.RA-W7IZBWU67MO887Rhfh2V75kCB_xyyrgKPfUmbLmvFo130_provenance.
- assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP588185.RAAwiC3J-t2Taf7sHHweGCvtok4TtpMCknu5NH_X-sKag130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588185.RAAwiC3J-t2Taf7sHHweGCvtok4TtpMCknu5NH_X-sKag130_provenance.
- NP951634.RAvHiAJHDnO-eSi6qivdqsLU1U5Hm2qtoty4j9UjBruB4130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951634.RAvHiAJHDnO-eSi6qivdqsLU1U5Hm2qtoty4j9UjBruB4130_provenance.
- NP588186.RAWJQzEjB1TVGSgWZj1FsgX5-Jc7sKAP1wOaI_Kxb1r3c130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588186.RAWJQzEjB1TVGSgWZj1FsgX5-Jc7sKAP1wOaI_Kxb1r3c130_provenance.
- assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP613590.RAlezckk4Z1rtJTodr8KCDFpEcVNocieqimq6bayK_YMA130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613590.RAlezckk4Z1rtJTodr8KCDFpEcVNocieqimq6bayK_YMA130_provenance.
- NP588184.RAs53QGm2PynlscJ_pUJRz0JC0lNUjjDjQROESO7Foj5k130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588184.RAs53QGm2PynlscJ_pUJRz0JC0lNUjjDjQROESO7Foj5k130_provenance.
- NP588190.RAuBcu2aEIZFz4wR1T9gfD3xt-EKmHcG5MczdkmsAZWI8130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588190.RAuBcu2aEIZFz4wR1T9gfD3xt-EKmHcG5MczdkmsAZWI8130_provenance.
- NP265631.RAGM1dxlHRpeb1MlhQyAMTW2-lCFdaM9eAuZU1tK9p1pc130_assertion description "[We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP265631.RAGM1dxlHRpeb1MlhQyAMTW2-lCFdaM9eAuZU1tK9p1pc130_provenance.